Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM4O17U)

Drug Name
VLTS-589 Drug Info
Synonyms Deltavasc; Del-1 gene therapy, Valentis; Gene therapy (Del-1, PINC), Valentis
Indication
Disease Entry ICD 11 Status REF
Peripheral vascular disease BD4Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM4O17U

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-V/beta-3 (ITGAV/B3) TT69TQN ITAV_HUMAN-ITB3_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Integrin alpha-V/beta-3 (ITGAV/B3) DTT ITGAV-ITGB3 3.916 4.104 5.776 4.121
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Peripheral vascular disease
ICD Disease Classification BD4Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Integrin alpha-V/beta-3 (ITGAV/B3) DTT ITGAV-ITGB3 8.19E-02 -0.16 -0.46
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00068133) Trial of VLTS-589 in Subjects With Intermittent Claudication. U.S. National Institutes of Health.
2 AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35.